Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $103.01 USD
Change Today -1.71 / -1.63%
Volume 235.0
As of 8:10 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

sanofi (SNYNF) Snapshot

Open
$103.01
Previous Close
$104.72
Day High
$103.01
Day Low
$103.01
52 Week High
09/22/14 - $115.06
52 Week Low
01/6/15 - $87.97
Market Cap
136.4B
Average Volume 10 Days
144.4
EPS TTM
--
Shares Outstanding
1.3B
EX-Date
05/11/15
P/E TM
--
Dividend
$2.85
Dividend Yield
3.73%
Current Stock Chart for SANOFI (SNYNF)

sanofi (SNYNF) Details

Sanofi researches, develops, and markets various therapeutic solutions. Its products comprise diabetes solutions, including Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; and Afrezza, an inhaled insulin to improve glycemic control, as well as Toujeo, an insulin glargine. The company also offers Cerezyme to treat gaucher disease; Myozyme/Lumizyme for the pompe disease treatment; Fabrazyme for fabry disease treatment; and Aldurazyme to treat mucopolysaccharidosis type I, as well as provides Aubagio and Lemtrada for multiple sclerosis. In addition, it provides Jevtana for prostate cancer; Taxotere for the treatment of breast, non-small cell lung, prostate, gastric, and head and neck cancers; Thymoglobulin to treat acute rejection in organ transplantation, aplastic anemia, and graft-versus-host diseases; Eloxatin for colorectal cancer; Mozobil for treating hematologic malignancies; and Zaltrap for oxaliplatin resistant metastatic colorectal cancer. Further, the company offers other prescription drugs, such as Plavix for atherothrombosis and acute coronary syndrome; Lovenox for the treatment and prevention of deep vein thrombosis and acute coronary syndromes; Aprovel/CoAprovel for hypertension; Renagel/Renvela to treat chronic kidney disease; Depakine for epilepsy; Synvisc/Synvisc-One for the treatment of pain associated with osteoarthritis of the knee; Stilnox/Ambien/Myslee to treat sleep disorders; Multaq for atrial fibrillation; Allegra for the treatment of allergic rhinitis and urticarial; Actonel for osteoporosis and paget's disease; and Auvi-Q/Allerject for the treatment of severe allergic reactions. Additionally, it offers consumer health care products and generic medicines; and vaccine and animal health products. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

113,496 Employees
Last Reported Date: 03/11/15
Founded in 1973

sanofi (SNYNF) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

sanofi (SNYNF) Key Developments

Innate Pharma S.A. Enters Collaboration Agreement with Sanofi on ADC Using Site-Specific Conjugation Tech

Innate Pharma SA announced that it has entered into a collaboration agreement with Sanofi to apply Innate Pharma's site-specific conjugation technology to the development of new Antibody Drug Conjugates or ADC. Sanofi-Aventis Recherche & Développement, the French R&D affiliate of Sanofi, will evaluate site-specific payload conjugation to enhance ADC pharmacokinetics, efficacy and safety and has the option to enter into a licencing agreement with Innate Pharma on this technology. Other terms of the agreement are undisclosed. Innate Pharma's coupling technology uses bacterial transglutaminase (BTG) enzyme. It aims to address the heterogeneity associated with traditional ADC coupling technologies which limits the therapeutic index of antibody conjugates. With Innate Pharma's technology, a single point mutation in the antibody's heavy chain generates either two or four specific enzyme-recognition sites, and linkers have been optimized to couple quantitatively at these positions.

Schrodinger Signs Drug Discovery Collaboration with Sanofi

Schrodinger signed a multi-year early drug discovery collaboration with Sanofi. Under the contract, Schrodinger will offer target analysis and validation to lead identification and lead optimisation for around ten drug discovery programmes. Schrodinger is to receive up to USD 120 million, which includes preclinical milestones. A new enterprise informatics system will also facilitate real-time collaboration between computational designers and medicinal chemists and will serve as the communications and project management platform for researchers across both firms.

Sanofi Announces Executive Changes

Sanofi has appointed Guido Businger as its new general director. Businger is replacing Fabrizio Guidi, who headed up Sanofi's subsidiary in Turkey. Businger, who has been working at Sanofi in Switzerland since 2004, was most recently head of the neurology division for Germany, Austria and Switzerland.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SNYNF:US $103.01 USD -1.71

SNYNF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $297.05 USD +0.60
Amgen Inc $163.58 USD -3.29
Bayer AG €133.32 EUR -4.43
Gilead Sciences Inc $101.38 USD -1.96
GlaxoSmithKline PLC 1,576 GBp -20.50
View Industry Companies
 

Industry Analysis

SNYNF

Industry Average

Valuation SNYNF Industry Range
Price/Earnings 25.8x
Price/Sales 3.3x
Price/Book 2.0x
Price/Cash Flow 16.3x
TEV/Sales 2.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANOFI, please visit www.sanofi.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.